M. Inoue et al., Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes, METABOLISM, 49(11), 2000, pp. 1400-1405
Human serum paraoxonase (PON1) is associated with high-density lipoprotein
(HDL) and inhibits the oxidation of low-density lipoprotein (LDL) in vitro,
suggesting that PON1 protects against atherosclerosis. We detected 3 polym
orphisms of the PON1 gene and investigated PON1 enzyme activities as paraox
onase (PON), arylesterase (ARYL) and diazoxonase (DIAZ), and serum PON1 con
centration in 106 patients with type 2 diabetes and 161 control subjects. A
ll 3 enzyme activities and specific activities of PON1 in diabetic patients
were significantly lower than those in controls, while there was no differ
ence in serum PON1 concentration between the patient and control groups. Th
e specific activities of PON, ARYL, and DIAZ in patients were 6.82 +/- 3.14
nmol.min(-1) U-1 (mean +/- SD, U; unit for serum PON1 concentration), 4.77
+/- 0.17 mu mol min(-1) U-1, and 193 +/- 92 nmol min(-1).U-1, respectively
, whereas those in controls were 9.33 +/- 3.92 nmol.min(-1).U-1, 5.36 +/- 0
.14 mu mol min(-1).U-1, and 242 +/- 103 nmol.min(-1) U-1, respectively. The
re was no significant difference in the allelic frequencies of -108C/T, 55L
/M, or 192Q/R between the patient and control groups. When each enzyme acti
vity was compared between the patient and control groups in each genotype s
ubgroup, all activities were lower in the patient group. The PON and ARYL a
ctivities were lower in patients with retinopathy or nephropathy than in th
ose without such complications, and the ARYL activity was also lower in pat
ients with neuropathy. In conclusion, all specific enzyme activities of PON
1 were lower in patients with type 2 diabetes independent of the -108C/T, 5
5L/M, or 192Q/R polymorphism, and this impaired PON1 function may he involv
ed in development of diabetic microangiopathy. Copyright (C) 2000 by W.B. S
aunders Company.